Heat Biologics Inc. (NASDAQ:HTBX) does about 31.46M shares in volume on a normal day but saw 9129881 shares change hands in Friday trading. The company now has a market cap of 184.20M USD and an enterprise value of about $149.63M. Its current market price is $1.34, marking an increase of 8.06% compared to the previous close of $1.24. The 52 week high reached by this stock is $4.30 whilst the lowest price level in 52 weeks is $0.19. The script in recent trading has seen the stock touch a high of $1.42 and a low of $1.22.

Heat Biologics Inc. (HTBX) has a 20-day trading average at $1.6855 and the current price is -68.84% off the 52-week high compared with 587.18% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.6147 and its 200-day simple moving average is $0.7998. If we look at the stock’s price movements over the week, volatility stands at 14.87%, which decreases to 11.18% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 43.90 to suggest the stock is neutral.

3 analysts observing the Heat Biologics Inc. (HTBX) stock have set the 12-month price targets for the company’s shares at between $5.00 and $5.00. The median price target is 73.2% away from the current levels at $5.00.

FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 20, 2016 when ROTH Capital initiated the stock to “Buy” and issued a price target of. H.C. Wainwright initiated its price target at $13.

The current price level is -22.41%, -16.44%, and 68.46% away from its SMA20, SMA50, and SMA200 respectively, with the HTBX price moving above the 50-day SMA on August 28. Heat Biologics Inc. (HTBX) stock is down -2.90% over the week and -41.48% over the past month. Its price is 182.11% year-to-date and 152.83% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.05 above consensus estimates by $0.04. The company’s next earnings report is expected on 11/12/2020, with forecasts estimating quarterly EPS at -$0.03 and -$0.2 for whole year. HTBX’s earnings per share are forecast to grow by 66.70% this year and -20.00% over next year. Expected sales for next quarter are $500k, which analysts say will come at $1.99 million for the current fiscal year and next year at $2.36 million. In addition, estimates put the company’s current quarterly revenue at an average of $500k.

Its 12-month price target is $5.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.00.

Outstanding shares total 87.93M with insiders holding 6.04% of the shares and institutional holders owning 13.56% of the company’s common stock. The company has a return on investment of -151.80% and return on equity of -77.30%. The beta has a value of 0.45. Price to book ratio is 2.48 and price to sales ratio is 52.63.

According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has added its position in Heat Biologics Inc. (HTBX) to 1,999,287 shares, mirroring a recent increase by 56.35%. Vanguard Total Stock Market Index added 0.72 million shares of Heat Biologics Inc. common stock bringing its total worth to about $4.34 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which added 0.27 million shares to end up with 1,073,566 shares worth $2.33 million. Fidelity Extended Market Index Fu cut their holdings by -39.47% in the company over the course of the most recent quarter. It now holds a 0.19% position in Heat Biologics Inc. thanks to 0.25 million shares amounting to $0.54 million.